Journal
EUROPEAN JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY
Volume 6, Issue 3, Pages 147-161Publisher
AKADEMIAI KIADO ZRT
DOI: 10.1556/1886.2016.00029
Keywords
probiotics; Escherichia coli; Nissle; Symbioflor; human studies; applications
Categories
Funding
- SymbioPharm GmbH
Ask authors/readers for more resources
A century ago, Alfred Nissle discovered that intentional intake of particular strains of Escherichia coli could treat patients suffering from infectious diseases. Since then, one of these strains became the most frequently used probiotic E. coli in research and was applied to a variety of human conditions. Here, properties of that E. coli Nissle 1917 strain are compared with other commercially available E. coli probiotic strains, with emphasis on their human applications. A literature search formed the basis of a summary of research findings reported for the probiotics Mutaflor, Symbioflor 2, and Colinfant. The closest relatives of the strains in these products are presented, and their genetic content, including the presence of virulence, genes is discussed. A similarity to pathogenic strains causing urinary tract infections is noticeable. Historic trends in research of probiotics treatment for particular human conditions are identified. The future of probiotic E. coli may lay in what Alfred Nissle originally discovered: to treat gastrointestinal infections, which nowadays are often caused by antibiotic-resistant pathogens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available